Lannett Company, Inc. (LCI)


Seite 1 von 3
Neuester Beitrag: 21.04.23 15:45
Eröffnet am:05.08.17 02:38von: Chalifmann3Anzahl Beiträge:63
Neuester Beitrag:21.04.23 15:45von: VassagoLeser gesamt:17.219
Forum:Hot-Stocks Leser heute:7
Bewertet mit:
2


 
Seite: <
| 2 | 3 >  

23601 Postings, 6191 Tage Chalifmann3Lannett Company, Inc. (LCI)

 
  
    #1
2
05.08.17 02:38
https://finance.yahoo.com/quote/LCI/profile?p=LCI

Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. It offers solid oral, extended release, topical, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel, and injectable dosages. The company provides its products for various medical indications comprising glaucoma, muscle relaxant, migraine, anesthetic, congestive heart failure, gastrointestinal, cardiovascular, thyroid deficiency, central nervous system, urinary, dryness of the mouth, gout, hypertension, and gallstone. It also manufactures active pharmaceutical ingredients. Lannett Company, Inc. markets its products under the Diamox, Fioricet, Fiorinal, Lanoxin, MiraLAX, Imdur, Levoxyl/Synthroid, Metadate CD, Concerta, Procardia, Prilosec, Ditropan, Protonix, Salagen, Dyazide, and Actigall brands. The company sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with JSP, Summit Bioscience LLC, HEC Pharm Group, and Pharma Pass II LLC. Lannett Company, Inc. was founded in 1942 and is based in Philadelphia, Pennsylvania.  

677 Postings, 2796 Tage cfgiHeute mit vorläufigen Zahlen

 
  
    #2
09.08.17 19:40
"While our industry is currently facing challenges, Lannett is strong and we have put in place a number of initiatives to position the company for long-term growth," said Arthur Bedrosian, chief executive officer of Lannett.  "Approximately 80% of our marketed products continue to be i ...
 

Optionen

165 Postings, 3814 Tage stereotyp72LCI: 53% short of float

 
  
    #3
24.02.18 13:03
http://shortsqueeze.com/?symbol=lci&submit=Short+Quote%E2%84%A2
Die Glattstellungskäufe dürften sehr schwierig werden, v.a. wenn mehr als 100% der Aktien in institutionellem Besitz sind. https://www.nasdaq.com/symbol/lci/institutional-holdings  

165 Postings, 3814 Tage stereotyp72LCI -57% wg. Gewinnwarnung

 
  
    #4
20.08.18 16:43
Der heutige Kurseinbruch ist völlig übertrieben, vermutlich handeln hauptsächlich Daytrader den Kurs runter, die werden ihre Shortpositionen aber wohl nicht sehr lange halten und die Eindeckungskäufe sorgen dann hoffentlich für eine Gegenbewegung.  

11568 Postings, 2501 Tage VassagoLCI 5,57$ (-59%)

 
  
    #5
20.08.18 18:13

165 Postings, 3814 Tage stereotyp72...

 
  
    #6
20.08.18 22:28
Die haben irgendwelche Exklusivrechte für einige Generika verloren, aber die genannten Mittel gibt es praktisch überall von unzähligen Herstellern und Distributoren, nur die Markennamen sind unterschiedlich.  

24089 Postings, 7552 Tage harry74nrwKaum O/S da könnte was gehen

 
  
    #7
1
21.08.18 13:17
Einnahmen fallen ab März 2019 weg!  

332 Postings, 2120 Tage Jannes@harry74nrw

 
  
    #8
22.08.18 15:41
Danke für die Information! Denke mal, daß hier was gehen wird - zumal ausreichend Zeit verbleibt, um auf den Ausfall zu reagieren. Das Ding ist über 50% runter... unglaublich...  

Optionen

24089 Postings, 7552 Tage harry74nrwHatte gestern vor dem Start zugeschlagen

 
  
    #9
22.08.18 16:06
Heute haben in DE https://www.ariva.de/lannett-aktie/times_and_sales?boerse_id=131
einige weiter gekauft, in USA vor den Earnings kommenden Di sehr sehr ruhig, kaum Rebound bisher, ich tippe auf fast 100 % Algohandel.
Märze 2019 fallen ca. Erträge weg und dann der Kursverlauf?.....
We will see
Toi toi  

24089 Postings, 7552 Tage harry74nrwca 30 % Erträge weg.....Touchscreen verschluckt ;(

 
  
    #10
22.08.18 16:08
2/3 bleiben und neue Zulassungen in den kommenden Monaten
 

24089 Postings, 7552 Tage harry74nrwKommenden Di

 
  
    #11
22.08.18 16:33

24089 Postings, 7552 Tage harry74nrw58 % ! Short

 
  
    #12
22.08.18 16:52
http://shortsqueeze.com/?symbol=lci&submit=Short+Quote™
Das ist schon gefährlich, aber sonst stünde die Aktie auch bei über 60 $  

165 Postings, 3814 Tage stereotyp72es kann auch schnell wieder hoch gehen

 
  
    #13
23.08.18 03:32
Bei Aegean (ANW) sah es fundamental noch viel übler aus, aber schon die Meldung über eine neue Kreditlinie und Partnerschaft ließ den Kurs anspringen. Bei den stark leerverkauften Nebenwerten besteht zumindest die Chance, dass Großaktionäre ihre Positionen so weit aufstocken, sodass die offenen Short-Positionen gar nicht mehr geschlossen werden können.  

24089 Postings, 7552 Tage harry74nrw3,12 $ Jahreserlöse

 
  
    #14
23.08.18 09:03
https://www.tickerreport.com/banking-finance/...itter_impression=true

Der Markt hat noch Panikmodus plus shorties

Baue mir eine langfristige Position auf, Firma steht seit über 60 Jahren und hat eine Produkte in der Pipeline und im Verkauf, empfehle jedem hierzu das transcript der letzten earnings.  

24089 Postings, 7552 Tage harry74nrwSEC 8K

 
  
    #15
23.08.18 13:40
Ankündigung kommender Woche
http://app.quotemedia.com/data/...rmType=8-K&dateFiled=2018-08-23

Exhibit 99.1






                
§

          

Contact:§
                
§
Robert Jaffe


                
§

                
§

                
§
Robert Jaffe Co., LLC


                
§

                
§

                
§
(424) 288-4098



LANNETT PROVIDES UPDATE ON CONTRACT RENEWAL

WITH JEROME STEVENS PHARMACEUTICALS



—Company Announces Preliminary Fiscal 2018 Fourth-Quarter and Full-Year Financial Results; To Host Conference Call Today at 8 a.m. ET—



Philadelphia, PA — August 20, 2018 — Lannett Company, Inc. (NYSE: LCI) today said that its distribution agreement with Jerome Stevens Pharmaceuticals (JSP), which expires on March 23, 2019, will not be renewed.



“The Steinlauf family advised us this past Friday evening that they will not renew our agreement to distribute three JSP products: Butalbital, Aspirin, Caffeine with Codeine Phosphate Capsules USP, Digoxin Tablets USP and Levothyroxine Sodium Tablets USP, upon its expiration in March 2019,” said Tim Crew, chief executive officer of Lannett.  “The family has assured us of a continuous supply of the products through March of next year.  These products remain valuable assets for us and are expected to significantly contribute to our financial performance in fiscal 2019.



“While we are disappointed, and intend to redouble our continuing efforts to explore options for addressing our capital structure, we have been preparing for this contingency, knowing that this outcome was a possibility.  Accordingly, we have been focused on improving our already strong base commercial business of more than 100 currently marketed products.  Since the beginning of this year, we added new products to our offering and expanded our customer base.  We continued to streamline our operations.  Specifically, we successfully launched eight new products in the first seven months of calendar 2018, which we estimate will add net sales in excess of $50 million in fiscal 2019, and in addition to our launches, we completed several transactions to add more than 25 market-ready or near-market-ready product lines to our pipeline.  Importantly, we continue to make excellent progress advancing other previously approved products toward launch and plan to commence marketing a substantial number of them in the coming months and throughout fiscal 2019.



“In addition, in our current fiscal year, we have already submitted four drug applications associated with two product families, implemented a restructuring plan at our Cody Laboratories subsidiary and streamlined our product distribution function.



“Looking ahead, our team is actively evaluating a number of additional potential transactions to add even more products to our portfolio to grow revenues and profits, and diversify our business.  We have more than 20 owned and partnered drug product applications currently





pending at the FDA, and anticipate a significant number of product approvals in fiscal 2019.  We also expect to expand restructuring initiatives to further reduce expenditures.  Finally, we are evaluating the impact of this contract ending in March 2019 on our goodwill.”



Preliminary Fiscal 2018 Fourth Quarter and Full Year Financial Results



For the fiscal 2018 fourth quarter, net sales are expected to be approximately $171 million, GAAP loss per share attributable to Lannett to be between $0.30 and $0.32 and Adjusted earnings per diluted share attributable to Lannett to be between $0.62 and $0.64.  For the prior-year fourth quarter, the company recorded net sales $139.1 million, GAAP net income attributable to Lannett of $5.7 million, or $0.15 per diluted share, and Adjusted net income attributable to Lannett of $15.1 million, or $0.40 per diluted share.



For the fiscal 2018 full year, net sales are expected to be approximately $685 million, GAAP earnings per diluted share attributable to Lannett to be between $0.73 and $0.75 and Adjusted earnings per diluted share attributable to Lannett to be between $3.08 and $3.10.  For the fiscal 2017 full year, net sales were $637.3 million, GAAP net loss attributable to Lannett was $0.6 million, or $0.02 per share, and Adjusted net income attributable to Lannett was $107.9 million, or $2.86 per diluted share.



Commenting on the company’s preliminary financial results for the fiscal 2018 fourth quarter and full year, Crew said, “Our financial performance was within our expected range, with revenue and adjusted net income solidly improved over last year.  And, based on the preliminary results, we remain well within our debt financial covenant, and we expect to continue to meet these requirements throughout fiscal 2019.”



Lannett will report full financial results for its fiscal 2018 fourth quarter and full year on Tuesday, August 28, 2018, after the market closes.  Lannett management will host a conference call that same afternoon at 4:30 p.m. ET to review the company’s performance and answer questions.



Special Conference Call Information, and Forward-Looking Statements



Today at 8 a.m. ET, the company will host a conference call to discuss today’s announcement.  The conference call will be available to interested parties by dialing 866-436-9172 from the U.S. or Canada, or 630-691-2760 from international locations, passcode 47456215.  The call will be broadcast via the Internet at www.lannett.com.  Listeners are encouraged to visit the website at least 10 minutes prior to the start of the scheduled presentation to register, download and install any necessary audio software.  A playback of the call will be archived and accessible on the same website for at least three months.



Discussion during the conference call may include forward-looking statements regarding such topics as, but not limited to, the company’s financial status and performance, regulatory and

 

24089 Postings, 7552 Tage harry74nrwShortangriff geht weiter

 
  
    #16
23.08.18 16:40
Niveau vor 2012 erreicht, bevor die Aktie Verträge Produktion in heutigem Umfang hatte,
werde die Aktie in dem Bereich nachkaufen, keine Derivate!  

24089 Postings, 7552 Tage harry74nrwMein Packerl ist geschnürt

 
  
    #18
23.08.18 17:20

Shorts haben vielleicht das Wochentief gesehen, ohne Gewähr

 

11568 Postings, 2501 Tage VassagoLannett Company

 
  
    #19
23.08.18 18:19

"Lannett will report full financial results for its fiscal 2018 fourth quarter and full year on Tuesday, August 28, 2018, after the market closes"

Die Frage ist halt wieviel Mio. $ Umsatz Lannett verliert durch den Rückzug von JSP. Wenn man den Gerüchten glauben schenken mag, dann könnten es bis zu 200 Mio. $ sein. Gemessen am FY18-Jahresumsatz von ~ 685 Mio. $, wäre das schon ein enormer Umsatzeinbruch, den Lannett in FY19 nicht kompensieren kann.

 

24089 Postings, 7552 Tage harry74nrwVassago

 
  
    #20
23.08.18 19:25
So ist es, die Firmenquellen schreiben 29% andere bis zu 39 %, Fakt ist das es fast 7 Monate weg ist und laut letztem EarningsTranscript einiges neues Markt angekommen ist und neues kommen wird, ich schätze die Lücke auf ganz grob noch auf 100 bis 120 Mio, ausreichend um Darlehen zu bedienen und weiter zu machen. Cash sind ja über 100 Mio vorhanden, könnte man vorab tilgen und und ..  
derzeit sind Shorter am Werke vom Feinsten, orchestriert mit Medien. Conti hätte ich auch nicht seit abrutschen sehen.  
Am besten wartest du den Di ab und entscheidest dann ob...

Harry  

115 Postings, 3193 Tage LOGAN5lannett

 
  
    #21
23.08.18 20:28
Here's Why Lannett Company Fell as Much as 14.8% Today
The hits keep coming for this generic-drug manufacturer.
Maxx Chatsko
(TMFBlacknGold)
Aug 23, 2018 at 12:33PM
What happened

Shares of Lannett Company (NYSE:LCI) fell nearly 15% today and have now dropped 65% in the last five days. Earlier this week the company announced it will soon lose its single most important supply contract, an agreement with Jerome Stevens Pharmaceuticals (JSP) for a basket of pharmaceutical ingredients that generated $253 million in net product sales in fiscal 2018. The contract will expire in March 2019.

Today, the company disclosed through an SEC filing that it was re-evaluating the value of goodwill and certain long-lived assets reported on its balance sheet in connection with the JSP contract. While a final decision hasn't been made about the size of the impairment charge that will be taken in the fiscal first quarter of 2019, Lannett Company reported $339.6 million goodwill on its balance sheet at the end of June (the end of fiscal 2018). Wall Street is preparing for this to hurt.

As of 11:55 a.m. EDT, the stock had settled to a 10% loss.



So what

The need to take a large impairment charge isn't surprising, but it wasn't the only material information announced today. While the company won't report full-year fiscal 2018 results until Aug. 28, it provided some details about the last full year of operations in today's SEC filing. The extra information is just adding salt to the very fresh wounds of investors reeling from the upcoming breakup with JSP.

Lannett Company reported that the value of products from the contract with JSP was $253 million in fiscal 2018, including $245.9 million from levothyroxine sodium tablets. It also disclosed that the thyroid medication's gross margin is approximately 60%.

That's up markedly from the $174 million in total net revenue reported for levothyroxine sodium tablets in fiscal 2017. This also appears to be the first time the company has disclosed profitability metrics related to the thyroid medication, which is helping Wall Street to determine just how big a drop to expect once the JSP agreement expires. Now investors have their answer: pretty big.
Now what

Unfortunately for individual investors caught in the volatility, Mr. Market might be right to run away from this generic pharma stock given the sudden surge in uncertainty. The soon-to-be-lost thyroid medication sees over 122 million prescriptions each year in the United States, making it the most prescribed medication in the country. The JSP contract -- to be scooped up by Amneal Pharmaceuticals in March 2019 -- represents about 10% of the total market for the drug.

The lost sales and (more important) earnings will be difficult to replace. That's going to make the $784 million in outstanding debt a much-bigger obstacle for the business from here, especially with the company valued at just $190 million now. While shares might seem like a bargain, I think investors should wait for more details before jumping into Lannett Company stock. The first batch of new information will be reported on the fiscal full-year 2018 earnings conference call on Aug. 28.  

24089 Postings, 7552 Tage harry74nrwKleiner rebound läuft

 
  
    #22
24.08.18 16:22
5 $ wären immerhin Bodenbildung und nächste Woche wäre Short gefährlich
 

332 Postings, 2120 Tage JannesDas übliche Spiel,

 
  
    #23
24.08.18 17:02
denke ich. Vor irgendwelchen Zahlen wird er Kurs hochgeprügelt, um dann wieder abzustürzen. Zuletzt von mir gesehen bei Aixtron... Ich spare mir mal den Link zum Chart. Hat einer `ne Idee, wie sich 339,6 Mio $ als "Godwill" für I/2019 auswirken werden? Mir macht das Bauchweh, weil die Trader nicht erkennen werden, daß sich das wohl eher um einen vorweggenommenen "worst case" für 2019 handeln wird.  

Optionen

24089 Postings, 7552 Tage harry74nrwJannes

 
  
    #24
24.08.18 17:25
Hochgeprügel? Vor den Zahlen die ohnehin fast jeder kennt......meiner Ansicht nach macht das keinen Sinn. Der Kurs stand vor einigen Wochen 3 x höher. Und der Umsatzverlust macht ca 1/3 aus ab 1.4.2019......
Der Kurs fast bankrott und große Verwässerung plus ähnliches ein, Shorter haben da ganze Arbeit geleistet.
Bis dann  

24089 Postings, 7552 Tage harry74nrwGünstige Aktien unter 10 $, Pr läuft

 
  
    #25
1
26.08.18 19:03
https://www.marketbeat.com/slideshows/...-stocks-to-buy-now-under-10/
Stock Price: $5.15
P/E Ratio: 1.8
Consensus Rating: Hold
Ratings Breakdown: 0 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $24.8750 (383.0% Upside)

Lannett logoLannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral, extended release, topical, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel, and injectable dosages. It also provides its products for various medical indications comprising glaucoma, cholesterol, muscle spasm, migraine, pain management, cardiovascular, antipsychosis, gastrointestinal, urinary, bronchospasms, respiratory, gallstone, congestive heart failure, thyroid deficiency, central nervous system, and gout. In addition, the company manufactures active pharmaceutical ingredients; and markets its products under the Diamox, Lipitor, Lioresal, Fioricet, Fiorinal, Lanoxin, Prolixin, MiraLAX, Imdur, Levoxyl/Synthroid, Metadate CD, Concerta, Procardia, Prilosec, Ditropan, Protonix, Imitrex, Brethine, Tussionex, and Actigall brands. Further, it sells pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with JSP, Summit Bioscience LLC, HEC Pharm Group, and Pharma Pass II LLC. Lannett Company, Inc. was founded in 1942 and is based in Philadelphia, Pennsylvania.  

Seite: <
| 2 | 3 >  
   Antwort einfügen - nach oben